C4X Discovery Holdings PLC
LSE:C4XD

Watchlist Manager
C4X Discovery Holdings PLC Logo
C4X Discovery Holdings PLC
LSE:C4XD
Watchlist
Price: 12 GBX 27.32% Market Closed
Market Cap: 30.3m GBX
Have any thoughts about
C4X Discovery Holdings PLC?
Write Note

C4X Discovery Holdings PLC
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

C4X Discovery Holdings PLC
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
C4X Discovery Holdings PLC
LSE:C4XD
Current Portion of Long-Term Debt
ÂŁ253k
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Current Portion of Long-Term Debt
ÂŁ4.3m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Current Portion of Long-Term Debt
ÂŁ146k
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Current Portion of Long-Term Debt
ÂŁ129k
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Current Portion of Long-Term Debt
ÂŁ1.6m
CAGR 3-Years
-7%
CAGR 5-Years
170%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Current Portion of Long-Term Debt
ÂŁ1.4m
CAGR 3-Years
-12%
CAGR 5-Years
48%
CAGR 10-Years
24%
No Stocks Found

C4X Discovery Holdings PLC
Glance View

Market Cap
30.3m GBX
Industry
Life Sciences Tools & Services

C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).

C4XD Intrinsic Value
43.44 GBX
Undervaluation 72%
Intrinsic Value
Price

See Also

What is C4X Discovery Holdings PLC's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
253k GBP

Based on the financial report for Jan 31, 2024, C4X Discovery Holdings PLC's Current Portion of Long-Term Debt amounts to 253k GBP.

What is C4X Discovery Holdings PLC's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
5%

Over the last year, the Current Portion of Long-Term Debt growth was -23%. The average annual Current Portion of Long-Term Debt growth rates for C4X Discovery Holdings PLC have been 5% over the past three years .

Back to Top